Transient Ischemic Attack

A transient ischemic attack (TIA) is a stroke that comes and goes quickly. The symptoms are the same as a stroke, but do not last as long.

Programs + Services

Stroke Center

Tufts Medical Center offers comprehensive stroke treatment, prevention, therapy and long-term management for a wide range of cerebrovascular disorders.
More information about programs and services

Doctors + Care Team

David E. Thaler, MD, PhD, FAHA
Request Appointment for David E. Thaler, MD, PhD, FAHA

David E. Thaler, MD, PhD, FAHA

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Neurologist-in-Chief, Department of Neurology, Tufts Medical Center; Chair and Professor, Department of Neurology, Tufts University School of Medicine
Department(s): Neurology
Appt. Phone: 617-636-4948
Fax #: 617-636-8199

Stroke

View Full Profile for David E. Thaler, MD, PhD, FAHA
Joshua Kornbluth, MD

Joshua Kornbluth, MD

Title(s): Medical Director, Neurosciences Critical Care Unit; Program Director, Neurology Residency and Neurocritical Care Fellowship; Neurologist; Assistant Professor, Tufts University School of Medicine
Department(s): Neurology
Appt. Phone: 617-636-4948
Fax #: 617-636-8199

Neurocritical care

View Full Profile for Joshua Kornbluth, MD
Adel M. Malek, MD, PhD
Request Appointment for Adel M. Malek, MD, PhD

Adel M. Malek, MD, PhD

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Chief, Neurovascular Surgery; Director, Cerebrovascular & Endovascular Division Professor, Tufts University School of Medicine
Department(s): Neurosurgery
Appt. Phone: 617-636-8200
Fax #: 617-636-7587

Aneurysms, arteriovenous malformations, dural fistulas, subarachnoid hemorrhage, intracranial atherosclerosis, arterial dissection

View Full Profile for Adel M. Malek, MD, PhD

Research + Clinical Trials

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA.

The purpose of this study is to learn if asundexian is safe for the participants, how it affects the body, and to look at how well it works to prevent future ischemic strokes in participants who already had had an acute non-cardioembolic ischemic stroke or high-risk TIA.
More information about research and clinical trials